Late-June 2026 clinical intelligence (June 16 to June 30). 15 high-signal trials across oncology, cardiometabolic, neurology and advanced modalities; featuring Regeneron's ROXI-CAT-II FXI antibody in cancer-associated VTE, Heidelberg's Teclistamab quintuplet in 1L newly diagnosed transplant-eligible MM, WSG's Sacituzumab + Pembrolizumab neoadjuvant TNBC program, Merck's KANDLELIT-015 MK-1084 in KRAS G12C+ Stage III NSCLC, Roche-Carmot's Petrelintide + Enicepatide combo and Boehringer's BI 3034701 obesity Phase 2b, plus T-MAXIMUM's MT027 intracerebroventricular universal CAR T in recurrent GBM.

Early-June 2026 clinical intelligence (June 1 to June 15). 15 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring GSK's Velzatinib challenging imatinib head-to-head in 1L GIST, Nurix's NX-5948 as the first BTK degrader in Phase 3, Regeneron's 1,570-patient Linvoseltamab MM program, APHP's 4,336-patient Low-EPI OHCA epinephrine trial, and Affinia's UPBEAT AFTX-201; the first AAV gene therapy for a hereditary cardiomyopathy.

Late-May 2026 clinical intelligence (May 16 to May 31). 16 high-signal trials across oncology, cardiometabolic, immunology, neurology and advanced modalities; featuring Novo Nordisk's CagriSema and AMAZE 8 head-to-heads against semaglutide, Janssen's JNJ-78934804 vs Guselkumab in parallel Crohn's and UC programs, Regeneron's 7,050-patient ROXI-PALISADE FXI program, Molecular Partners' DLL3 alpha-emitter, and AbbVie's NAAVIGATE AAV gene therapy in diabetic retinopathy.

Early-May 2026 clinical intelligence (May 1 to May 15). 15 high-signal trials across oncology, cardiometabolic, immunology and neurology; featuring Merck's Intismeran mRNA vaccine in resected NSCLC, parallel ADC Phase 3 programs from AbbVie and EMD Serono in refractory mCRC, Novartis DLL3 CAR-T in SCLC, and the Pelacarsen Lp(a)HORIZON extension at 5,700 patients across 492 sites.

Late-April 2026 clinical intelligence (Apr 16 to Apr 30). 15 high-signal trials across oncology, cardiometabolic & cardiopulmonary, immunology, advanced modalities and infectious disease; featuring BMS CD19 CAR-T in systemic sclerosis, Roche NXT007 vs Hemlibra, Janssen IL-23 head-to-head in Crohn's, and HELP iPSC-cardiomyocytes in heart failure.

Early-April 2026 U.S. clinical-trial announcements (Apr 1 to 14). 9 trials across cardiometabolic, oncology, infectious disease, and rare disease; featuring gene therapy for heart failure, pediatric CAR T, Marburg vaccine, and oral rare disease therapies.

Late-March 2026 U.S. clinical-trial announcements (Mar 14–31). 9 trials across precision oncology, rare disease, pulmonary disease, cardiometabolic, and sleep medicine; featuring targeted protein degradation, inhaled reformulations, and pivotal Phase 3 programs.

Early-March 2026 U.S. clinical-trial announcements (Mar 1–15). Phase 2–3 trials across oncology, neurology, rare & pulmonary diseases, infectious disease, and advanced gene-editing modalities; featuring 15 trials including CRISPR therapies, protein degraders, and novel anti-infectives.

Late-February 2026 U.S. clinical-trial activity (Feb 13–28). Oncology, neurology, infectious disease, rare disorders, and advanced genetic therapies; featuring 11 trials across precision oncology, gene editing, preventive immunology, and innovative trial designs.

Early-February 2026 U.S. clinical-trial activity (Feb 1–15). Phase 1–4 trials in breast cancer, prostate cancer, Alzheimer's disease, Parkinson's disease and colon cancer, with a focus on Phase 2 innovations.

Early-phase clinical trial intelligence from the U.S. highlighting newly announced Phase 1 and Phase 2 trials across oncology and neurodegenerative diseases.

A snapshot of newly announced and progressing early-phase clinical trials across oncology and neurodegenerative disease, with a focus on U.S. activity.